Drug metabolism in liver disease: Implications for therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 397-401

  Sonne, Jesper ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Drug metabolism; Liver disease

Indexed keywords

CYTOCHROME P450;

CONFERENCE PAPER; DOSE CALCULATION; DOSE LIVER FUNCTION RELATION; DRUG GLUCURONIDATION; DRUG MONITORING; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME SPECIFICITY; HUMAN; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

DRUG MONITORING; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0029809657     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00015     Document Type: Conference Paper

References (26)

1. Wilkinson GR, Schenker S. Drug disposition and liver disease. Drug Metab Rev 1975;4:139-75.
2. Williams RL, Mamalok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980;5:528-47.
3. Bircher J. Hepatic drug disposition in liver disease: consequences for dosage adjustments. In: Csomos G, Thaler H, eds. Clinical hepatology. Berlin: Springer-Verlag, 1983: 45-51.
4. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Adv Intern Med 1987;32:379-406.
5. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989;40:439.74.
6. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42-69.
7. Wilkinson GR. Influence of hepatic disease on pharmacokinetics. In: Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics. Spokane: Applied Therapeutics, 1991:116-38.
8. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569-73.
9. Andreasen PB, Ranek L, Statland BE, Tygstrup N. Clearance of antipyrine - dependence of quantitative liver function. Eur J Clin Invest 1974;4:129-34.
10. Roberts RK, Wilkinson GR, Branch RA, et al. Effects of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 1978;75:479-85.
11. Klotz U, Antonin KH, Brugel H, et al. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther 1977;21:430-6.
12. Piafsky KM, Sitar DS, Rango RE, et al. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977;296:1495-7.
13. Loft S, Sonne J, Døssing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1988;43:420-8.
14. Gugler R, Kurten JW, Jensen CJ, et al. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol 1979;15:341-7.
15. Patwardhan RV, Johnson RF, Hoyumpa A, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981;81:1006-11.
16. Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976;84:420-5.
17. Hasselström J, Eriksson S, Persson A, Rane A, Svensson JO, Säwe J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990;29:289-97.
18. Sonne J, Andreasen PB, Loft S, Døssing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 1990;11:951-6.
19. Klotz U, Rapp T, Muller WA. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 1978;13:55-60.
20. Homeida M, Jackson L, Roberts CJC. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J 1978;2:1048-50.
21. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
22. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-38.
23. Robin DW, Lee M, Hasan SS, Wood AJJ. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:630-7.
24. Kleinbloesem CH, van Harten J, Wilson JPH, Danhof M, van Brummelen, Breimer DD. Nifedipine: kinetics and hemo-dynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986;40:21-8.
25. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995;21:120-8.
26. Asconapé JJ, Penry JK. Use of antiepileptic drugs in the presence of liver and kidney disease: a review. Epilepsia 1982;23(suppl 1):S65-79.